Sign In
Buy TRCK
$0.643
-0.0072 (-1.11%)
At Close: Jul 31, 2026
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
07:00am, Thursday, 30'th Apr 2026
KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to K
VANCOUVER, BC / ACCESS Newswire / April 29, 2026 / Redwood AI Corp. (CSE:AIRX)(Frankfurt:Y0N, WKN:A422EZ) ("Redwood" or the "Company") is pleased to announce that its Chief Executive Officer, Louis Dr
Cognizant's Innovation Network a Fast Track to Enterprise Value
12:11pm, Tuesday, 28'th Apr 2026
Investment arm deepens firm's AI builder strategy by creating a direct pipeline from startup innovation to enterprise-scale implementation TEANECK, N.J., April 28, 2026 /PRNewswire/ -- Cognizant (Nas
Allied Critical Metals Announces Transformative U.S.$40 Million Financing Package to Fast-Track Tungsten Concentrates Production
07:30am, Friday, 24'th Apr 2026
Highlights: Strategic investment of U.S.$40 million comprised of U.S.$25 million equity financing and U.S.$15 million in project financing for the Vila Verde Pilot Plant. Allied Critical Metals is ful
CHALFONT ST GILES, England--(BUSINESS WIRE)--GE HealthCare announces first patient dosed in Phase 2/3 LUMINA trial for manganese-based MRI contrast agent under FDA Fast Track designation.
OAKLAND, Calif., April 23, 2026 /PRNewswire/ -- PG&E Corporation (NYSE: PCG) is on track to deliver solid financial results in 2026.
Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting
04:05pm, Wednesday, 22'nd Apr 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a the
The Hamilton Lane Credit Income Fund is now available to institutional and private wealth investors via the interval fund structure The firm's Private Infrastructure Fund is now offered in an interval
Margins Strengthened and Cash Flow Improved Despite a Temporary Dip in The Growth Trajectory. Full-Year Targets Remain on Track
02:20am, Wednesday, 22'nd Apr 2026
UPPSALA, SE / ACCESS Newswire / April 22, 2026 / Senzime (STO:SEZI) (OTCQX:SNZZF) - Senzime AB's (publ) interim report for January - March 2026 is now available on the company's website www.senzime.co
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
08:30am, Tuesday, 21'st Apr 2026
PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs, toda
BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors
AtaiBeckley Stock Skyrockets As Psychedelic Rally Extends On Trump Fast‑Track Order
02:36pm, Monday, 20'th Apr 2026
ATAI surged 28.1% in premarket trading as investors piled into the sector after the administration's weekend directive. The move sparked a broad wave of buying across psychedelic‑focused companies.
Duke Energy: 100-Year Dividend Track Record — But $103B Capex Is Compressing The Credit Cushion
02:22pm, Monday, 20'th Apr 2026
Duke Energy ended FY2025 with adjusted EPS of $6.31, covering its $4.22 annual dividend at approximately 1.49x. The company has paid a quarterly cash dividend for 100 consecutive years.
Race Day Starts Before You Get to the Track: StubHub and New Era Team Up for F1's North American Season and Beyond
08:30am, Monday, 20'th Apr 2026
NEW YORK--(BUSINESS WIRE)--StubHub and New Era announce a partnership that surfaces personalized merchandise offers to fans directly within the ticket purchase experience.
Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.
08:18am, Monday, 20'th Apr 2026
AtaiBeckley and Compass Pathways are two drugmakers developing psychedelic treatments for depression.
